<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129606</url>
  </required_header>
  <id_info>
    <org_study_id>TURBT-BP</org_study_id>
    <nct_id>NCT04129606</nct_id>
  </id_info>
  <brief_title>Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy</brief_title>
  <acronym>TURBT-BP</acronym>
  <official_title>Bladder Perforation Post-TURBT: Definition, Incidence and Natural History. A Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abdelwahab Hashem</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In view of sparse data of precise definition, risk factors, natural history and management of
      bladder perforation following Transurethral resection of bladder tumour (TURBT). We aim to
      correlate the relation between the site, depth and extent of resection with bladder
      perforation. Also, correlation between vertical depth, horizontal extent of resection and
      recurrence and progression of tumor
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of bladder perforation post-Transurethral resection of bladder tumour</measure>
    <time_frame>24 months</time_frame>
    <description>calculate the numbers of bladder perforation diagnosed by CT cystogram divided by the total number of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between the cystoscopical and radiological bladder perforation</measure>
    <time_frame>24 months</time_frame>
    <description>compare the numbers of bladder perforation diagnosed by CT cystogram by the number of bladder perforation described by surgeon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess the recurrence free rate in bladder perforation groups at 2 year follow up</measure>
    <time_frame>24 months</time_frame>
    <description>calculate the number of recurrence pf bladder tumor in bladder perforation at 2 year follow up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Bladder Urothelial Carcinoma</condition>
  <condition>Trauma</condition>
  <condition>Injuries</condition>
  <condition>Perforation of Bladder</condition>
  <condition>Recurrence Tumor</condition>
  <condition>Resection Margin</condition>
  <condition>Seeding, Neoplasm</condition>
  <arm_group>
    <arm_group_label>TURBT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Transurethral resection of bladder tumour</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Computed tomographic cystography</intervention_name>
    <description>CT cystogram performed after the procedure by the injection of 400mL of 1/4 saline-diluted contrast solution (meglumine ioxitalamate) with low-pressure infusion (60 cm gravity pressure) through the Foley catheter.</description>
    <arm_group_label>TURBT</arm_group_label>
    <other_name>CT cystography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  papillary bladder tumor (denovo or recurrent)

          -  resectable nodular bladder tumor

        Exclusion Criteria:

          -  Refuse to complete study requirements

          -  muscle invasive bladder tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nasr Eltabey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology and Nephrology Center</name>
      <address>
        <city>Mansoura</city>
        <state>Aldakahlia</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2019</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Abdelwahab Hashem</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Perforation of Bladder</keyword>
  <keyword>Bladder Cancer</keyword>
  <keyword>Resection Margin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Neoplasm Seeding</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

